Black Friday Sale: 20% off everything. Ends Tuesday 1 December, 11:59 pm AEDT.
For laboratory and research use only. Not for human consumption.  Sold exclusively to qualified researchers and licensed laboratories.

CATALOGUE  /  TESAMORELIN

TESAMORELIN 5MG

Tesamorelin, lyophilised powder in a sealed vial

Tesamorelin

Research peptide · Lyophilised powder in a sealed vial · for laboratory and research use only

Tesamorelin 5mg Quantity per vial: 5mg
$129.99$103.99
Secure card payments
Not a drug, food or cosmetic. For laboratory and research use only. Not for human consumption. This product has not been evaluated or approved by the US Food and Drug Administration (FDA) or the Australian Therapeutic Goods Administration (TGA), and it is not intended to diagnose, treat, cure or prevent any disease. Sold exclusively to qualified researchers and licensed laboratories.

Reagent specifications

CAS number218949-48-5
Molecular weight5136 g/mol (PubChem reference value)
StorageSealed, dry and dark at −20 °C or colder; −50 to −80 °C for long-term storage
Certificate of analysisAvailable on request · Request a COA

CAS number and molecular weight are reference values for the compound identity, from PubChem.

Compound identity

Compound classSynthetic growth hormone-releasing hormone (GHRH) analogue, 44 residues
Sequence (one-letter)(E)-hex-3-enoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2 (human GHRH(1-44) amide with an N-terminal hexenoyl group)
Molecular formulaC221H366N72O67S (free base, PubChem)
PubChem CID16137828
Other namesTH9507
Supplied asLyophilised powder, sealed vial
Quantity per vial5 mg
Intended useLaboratory and research use only

About Tesamorelin

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH): the full 44-amino-acid sequence of human GHRH, as the C-terminal amide, with a (E)-hex-3-enoyl group attached to the N-terminal tyrosine.1 It is an agonist at the GHRH receptor.

Titan Peptides supplies tesamorelin as a lyophilised powder in a sealed 5 mg vial, for laboratory and research use only. It is a research chemical: not a drug, food or cosmetic, and not for human consumption.

Status in Australia

Tesamorelin is not named in the Poisons Standard June 2026 (F2026L00633). The instrument does, however, list growth hormone releasing hormones (GHRHs) as a Schedule 4 group entry, also in Appendix D, clause 5, and a substance can be captured by a group entry rather than by its own name.2 Research-grade tesamorelin is not an approved therapeutic good in Australia. See research peptides and Australian law.

Laboratory handling & storage

Store the sealed vial dry, dark and frozen at −20 °C or colder (−50 to −80 °C for long-term storage), and let it reach room temperature in a desiccator before opening. The 44-residue sequence contains a methionine, which is prone to oxidation, and several asparagine and glutamine residues, which are prone to deamidation, so limit air exposure and keep solutions only briefly: aliquot a reconstituted stock into single-use tubes, freeze them and avoid freeze–thaw cycles. See how to store peptides and reconstituting peptides with bacteriostatic or sterile water for the reasoning behind each step.

Tesamorelin quick answers

What form is Tesamorelin supplied in?

Tesamorelin is supplied as a lyophilised (freeze-dried) powder in a sealed vial containing 5 mg, for laboratory and research use only. It is a research chemical, not a drug, food or cosmetic, and is not for human consumption.

What is tesamorelin's CAS number?

PubChem lists tesamorelin under CAS 218949-48-5 and CID 16137828, with the molecular formula C221H366N72O67S and a molar mass of 5136 g/mol. Its development code was TH9507.

Is tesamorelin related to ipamorelin?

Not structurally. Tesamorelin is a 44-residue analogue of GHRH and acts through the GHRH receptor. Ipamorelin is a five-residue synthetic peptide that acts through a GHRP-type receptor rather than the GHRH receptor. The two are separate compounds with unrelated sequences.

Is tesamorelin legal in Australia?

Tesamorelin is not named in the June 2026 Poisons Standard, although the instrument lists growth hormone releasing hormones as a Schedule 4 group entry. Research-grade tesamorelin is not an approved therapeutic good. Our guide to research peptides and Australian law explains how the Poisons Standard and the TGA's position on unapproved peptide products work.

References

  1. PubChem. Tesamorelin, CID 16137828. National Center for Biotechnology Information. Source
  2. Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 (Standard for the Uniform Scheduling of Medicines and Poisons No. 48), F2026L00633. Commenced 1 June 2026. Federal Register of Legislation. Source
Research use only. Not a drug, food or cosmetic. Tesamorelin is supplied strictly for laboratory and in-vitro research and is not for human consumption. It is not an approved therapeutic good in Australia, has not been evaluated or approved by the FDA or the TGA, and is not intended to diagnose, treat, cure or prevent any disease. Titan Peptides sells exclusively to qualified researchers and licensed laboratories.